Waystar closes Iodine acquisition for ~$459M cash + 16.6M shares; debt amended

Waystar Holding Corp.

Acquisition completed Oct 1, 2025; total consideration ~$458.6M cash plus 16.64M shares valued at $37.31/share.
Combined company unites financial and clinical AI; expands TAM by >15% with Iodine's 1,000+ hospital clients.
Waystar expects immediate accretion to gross margin and adjusted EBITDA margin; revenue and non-GAAP EPS accretive in 2027.
Credit facility amended: $250M incremental term loans, revolver increased to $500M, interest rates reduced.
Board expanded to 13; Lauren Young (Advent MD) appointed as Class II director.

item 1.01item 2.03item 3.02item 5.02item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.